capeserod capeserod capeserod (inn; development code sl65.0155) is a selective 5-ht4 receptor partial agonist with ki = 0.6 nm and ia = 40–50% (relative to serotonin). it potently enhances cognition, learning, and memory, and also possesses antidepressant effects. capeserod was in phase ii clinical trials around 2004–2006 for the treatment of memory deficits and dementia but no new information has surfaced since and it appears to have been abandoned. capeserodclinical dataatc codenoneidentifiers iupac name 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3--1,3,4-oxadiazol-2-one cas number769901-96-4 191023-43-5 (hcl)pubchem cid9805719iuphar/bps29chemspider7981479unii8163770l8pchemblchembl2027925comptox dashboard (epa)dtxsid60998277 chemical and physical dataformulac23h25cln4o4molar mass456.93 g·mol−13d model (jsmol)interactive image smiles c1cn(ccc1n2c(=o)oc(=n2)c3=cc(=c(c4=c3occo4)n)cl)ccc5=cc=cc=c5 inchi inchi=1s/c23h25cln4o4/c24-18-14-17(20-21(19(18)25)31-13-12-30-20)22-26-28(23(29)32-22)16-7-10-27(11-8-16)9-6-15-4-2-1-3-5-15/h1-5,14,16h,6-13,25h2key:mdbntxarngrhev-uhfffaoysa-n